MapLight Therapeutics, Inc. (MPLT)
About MapLight Therapeutics, Inc.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$161.2M
- Total assets
- $479.5M
- Market cap
- $1.3B
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $169.1M
- Operating income
- -$169.1M
- Net income
- -$161.2M
- EPS (basic)
- $-18.56
- EPS (diluted)
- $-18.56
Balance sheet
- Total assets
- $479.5M
- Current assets
- $324.7M
- Total liabilities
- $21.1M
- Current liabilities
- $16.2M
- Shareholders’ equity
- $458.4M
Cash flow
- Operating cash flow
- -$138.1M
- Investing cash flow
- -$323.2M
- Financing cash flow
- $469.8M
- Net cash flow
- $8.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.3B
- EPS (diluted)
- $-18.56
- Shares outstanding
- 34.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 27, 2025
MapLight Therapeutics, Inc. (MPLT) Stock Price
- Reported a net loss of $161.2M.
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MapLight Therapeutics, Inc..
Write a review
News about MapLight Therapeutics, Inc.
News & sentiment via Polygon.io
MapLight Therapeutics, Inc.: frequently asked questions
Is MapLight Therapeutics, Inc. an American company?
MapLight Therapeutics, Inc. is a US-based company headquartered in Redwood City, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is MapLight Therapeutics, Inc. headquartered?
MapLight Therapeutics, Inc. is headquartered in Redwood City, California, United States.
Is MapLight Therapeutics, Inc. publicly traded?
Yes — MapLight Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol MPLT on the NASDAQ.
What does MapLight Therapeutics, Inc. do?
MapLight Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
